Hedera Dx
Latest round
- Series A
Last raised
- May 2025
Total raised
- $31M
Investors
- 9
About Hedera Dx
Based in Switzerland, and founded in 2021 by its CEO, Tommi Lehtonen, CCO, Damien Lapray, CMO, and Christian Meisel, Hedera Dx SA, operates as a healthcare technology company that offers liquid biopsies for cancer patients having therapies. The company offers a liquid biopsy solution that includes blood drawing and sequencing for personalized treatment plans for circulating tumors. The company also provides a platform that helps to generate a patient’s tumor ctDNA sequence.
Who invested in Hedera Dx
9 investors across 2 rounds
See all investors in Hedera Dx
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hedera Dx
Who invested in Hedera Dx?
Hedera Dx has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hedera Dx raised?
Hedera Dx has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Hedera Dx last raise money?
Hedera Dx's most recent round on record is a Series A, in May 2025.
What does Hedera Dx do?
Based in Switzerland, and founded in 2021 by its CEO, Tommi Lehtonen, CCO, Damien Lapray, CMO, and Christian Meisel, Hedera Dx SA, operates as a healthcare technology company that offers liquid biopsies for cancer patients having therapies.
Where is Hedera Dx headquartered?
Hedera Dx is headquartered in Epalinges, Switzerland.
Which VCs invest in companies like Hedera Dx?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back healthcare it companies at Hedera Dx's stage. Their profiles are linked below.
VCs backing healthcare it startups at Series A
Raising like Hedera Dx? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.